Citius Oncology, Inc. CTOR Deferred Tax Assets, Valuation Allowance
Deferred Tax Assets, Valuation Allowance at other companies
Other financials
Where this comes from
Reported directly by Citius Oncology, Inc. in its filing.
Tagged under the XBRL concept us-gaap:DeferredTaxAssetsValuationAllowance.
The official record: Citius Oncology, Inc.’s 10-K, filed December 23, 2025, on SEC EDGAR. View the filing →
Ask your AI about Citius Oncology, Inc.'s deferred tax assets, valuation allowance.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Citius Oncology, Inc.'s deferred tax assets, valuation allowance?
- Citius Oncology, Inc. (CTOR) reported deferred tax assets, valuation allowance of $19.42M in Q3 2025.
- What is the long-term trend for Citius Oncology, Inc.'s deferred tax assets, valuation allowance?
- Over 2 years (2023 to 2025), Citius Oncology, Inc.'s deferred tax assets, valuation allowance has grown at a 119.2% compound annual growth rate (CAGR), from $4.04M to $19.42M.